Striatal and extrastriatal dopamine transporter in cannabis and tobacco addiction: A high-resolution PET study

Addiction Biology

Volumn 17, Issue 6, 2012, Pages 981-990

  Leroy, Claire ^a,e   Karila, Laurent ^f   Martinot, Jean Luc ^a,e,g   Lukasiewicz, Michaël ^f   Duchesnay, Edouard ^a,b,d,e,g   Comtat, Claude ^c   Dollé, Frédéric ^c   Benyamina, Amine ^f   Artiges, Eric ^a,e,g,h   Ribeiro, Maria Joao ^a,e   Reynaud, Michel ^f   Trichard, Christian ^a,h  

^a Pitié Salpêtrière Hospital   (France)

^b Maison de Solenn   (France)

^c DIF   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e University Paris Descartes   (France)

^f HÔPITAL PAUL BROUSSE   (France)

^g CEA SACLAY   (France)

^h Centre Hospitalier d'Orsay   (France)

Author keywords

Addiction; cannabis; HRRT; neuronal dopamine transporter; PET study; tobacco

Indexed keywords

DOPAMINE TRANSPORTER; PE 2I C 11; RADIOLIGAND; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN REGION; CANNABIS ADDICTION; CASE CONTROL STUDY; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; MALE; MESENCEPHALON; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; STRIATE CORTEX; THALAMUS; TISSUE DISTRIBUTION; TOBACCO DEPENDENCE;

ADULT; BASAL GANGLIA; BRAIN; CASE-CONTROL STUDIES; CAUDATE NUCLEUS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MALE; MARIJUANA ABUSE; NORTROPANES; POSITRON-EMISSION TOMOGRAPHY; PUTAMEN; RADIOPHARMACEUTICALS; SUBSTANTIA NIGRA; THALAMIC NUCLEI; TOBACCO USE DISORDER;

EID: 84868210063     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2011.00356.x     Document Type: Article

References (51)

1. Barkus E, Morrison PD, Vuletic D, Dickson J, Ell PJ, Pilowsky LS, Brenneisen R, Holt DW, Powell J, Kapur S, Murray RM, (2010) Does intravenous delta-9-tetrahydrocannabinol increase dopamine release? A SPET study. J Psychopharmacol. doi: 10.1177/0269881110382465. [epub ahead of print].
2. Barrett SP, Boileau I, Okker J, Pihl RO, Dagher A, (2004) The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [11C]raclopride. Synapse 54: 65-71.
3. Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, Windhorst AD, van Gerven JM, Ramsey NF, Lammertsma AA, Kahn RS, (2009) Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 34: 759-766.
4. Brett M, Anton J, Valabregue R, Poline J, (2002) Region of interest analysis using an SPM toolbox. Paper presented at the 8th International Conference on Functional Mapping of the Human Brain, Sendai, Japan.
5. Brody AL, Mandelkern MA, Olmstead RE, Allen-Martinez Z, Scheibal D, Abrams AL, Costello MR, Farahi J, Saxena S, Monterosso J, London ED, (2009) Ventral striatal dopamine release in response to smoking a regular vs a denicotinized cigarette. Neuropsychopharmacology 34: 282-289.
6. Brody AL, Mandelkern MA, Olmstead RE, Scheibal D, Hahn E, Shiraga S, Zamora-Paja E, Farahi J, Saxena S, London ED, McCracken JT, (2006) Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. Arch Gen Psychiatry 63: 808-816.
7. Brody AL, Olmstead RE, London ED, Farahi J, Meyer JH, Grossman P, Lee GS, Huang J, Hahn EL, Mandelkern MA, (2004) Smoking-induced ventral striatum dopamine release. Am J Psychiatry 161: 1211-1218.
8. Cheer JF, Wassum KM, Heien ML, Phillips PE, Wightman RM, (2004) Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci 24: 4393-4400.
9. Court JA, Lloyd S, Thomas N, Piggott MA, Marshall EF, Morris CM, Lamb H, Perry RH, Johnson M, Perry EK, (1998) Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use. Neuroscience 87: 63-78.
10. Dagher A, Bleicher C, Aston JA, Gunn RN, Clarke PB, Cumming P, (2001) Reduced dopamine D1 receptor binding in the ventral striatum of cigarette smokers. Synapse 42: 48-53.
11. Di Chiara G, Imperato A, (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85: 5274-5278.
12. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM, Innis RB, (2002) Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry 10: 36-43.
13. Fehr C, Yakushev I, Hohmann N, Buchholz HG, Landvogt C, Deckers H, Eberhardt A, Klager M, Smolka MN, Scheurich A, Dielentheis T, Schmidt LG, Rosch F, Bartenstein P, Grunder G, Schreckenberger M, (2008) Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. Am J Psychiatry 165: 507-514.
14. Fleckenstein AE, Metzger RR, Wilkins DG, Gibb JW, Hanson GR, (1997) Rapid and reversible effects of methamphetamine on dopamine transporters. J Pharmacol Exp Ther 282: 834-838.
15. Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frackowiak RSJ, (1995) Statistical parametric maps in functional imaging. A general linear approach. Hum Brain Mapp 2: 189-210.
16. Gardner EL, (2005) Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav 81: 263-284.
17. Goldstein RZ, Volkow ND, (2002) Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 159: 1642-1652.
18. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ, (1997) Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6: 279-287.
19. Hall H, Halldin C, Guilloteau D, Chalon S, Emond P, Besnard J, Farde L, Sedvall G, (1999) Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2I. Neuroimage 9: 108-116.
20. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO, (1991) The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86: 1119-1127.
21. Hirvonen J, Johansson J, Teras M, Oikonen V, Lumme V, Virsu P, Roivainen A, Nagren K, Halldin C, Farde L, Hietala J, (2008) Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility. J Cereb Blood Flow Metab 28: 1059-1069.
22. de Jong HW, van Velden FH, Kloet RW, Buijs FL, Boellaard R, Lammertsma AA, (2007) Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner. Phys Med Biol 52: 1505-1526.
23. Kahlig KM, Galli A, (2003) Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine. Eur J Pharmacol 479: 153-158.
24. Kirkham TC, (2005) Endocannabinoids in the regulation of appetite and body weight. Behav Pharmacol 16: 297-313.
25. Koob GF, Le Moal M, (2006) Neurobiology of Addiction. London: Academic Press (Elsevier).
26. Laine TP, Ahonen A, Torniainen P, Heikkila J, Pyhtinen J, Rasanen P, Niemela O, Hillbom M, (1999) Dopamine transporters increase in human brain after alcohol withdrawal. Mol Psychiatry 4: 189-191, 104- 185.
27. Lammertsma AA, Hume SP, (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4: 153-158.
28. Leroy C, Comtat C, Trebossen R, Syrota A, Martinot JL, Ribeiro MJ, (2007) Assessment of 11C-PE2I binding to the neuronal dopamine transporter in humans with the high-spatial-resolution PET scanner HRRT. J Nucl Med 48: 538-546.
29. Maldjian JA, Laurienti PJ, Burdette JH, (2004) Precentral gyrus discrepancy in electronic versions of the Talairach atlas. Neuroimage 21: 450-455.
30. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH, (2003) An automated method for neuroanatomic and cytoarchitectonicatlas-based interrogation of fMRI data sets. Neuroimage 19: 1233-1239.
31. Messinis L, Kyprianidou A, Malefaki S, Papathanasopoulos P, (2006) Neuropsychological deficits in long-term frequent cannabis users. Neurology 66: 737-739.
32. Meyer JH, Gunn RN, Myers R, Grasby PM, (1999) Assessment of spatial normalization of PET ligand images using ligand-specific templates. Neuroimage 9: 545-553.
33. Montgomery AJ, Lingford-Hughes AR, Egerton A, Nutt DJ, Grasby PM, (2007) The effect of nicotine on striatal dopamine release in man: a [11C]raclopride PET study. Synapse 61: 637-645.
34. Newberg A, Lerman C, Wintering N, Ploessl K, Mozley PD, (2007) Dopamine transporter binding in smokers and nonsmokers. Clin Nucl Med 32: 452-455.
35. Picciotto MR, (2003) Nicotine as a modulator of behavior: beyond the inverted U. Trends Pharmacol Sci 24: 493-499.
36. Rivière D, Papadopoulos-Orfanos D, Poupon C, Poupon F, Coulon O, Poline J-B, Frouin V, Régis J, Mangin J-F, (2000) A Structural Browser for Human Brain Mapping. In Proceedings of the 6th Human Brain Mapping, San Antonio, Texas. NeuroImage 11: 912.
37. Scott DJ, Domino EF, Heitzeg MM, Koeppe RA, Ni L, Guthrie S, Zubieta JK, (2007) Smoking modulation of mu-opioid and dopamine D2 receptor-mediated neurotransmission in humans. Neuropsychopharmacology 32: 450-457.
38. Sevy S, Smith GS, Ma Y, Dhawan V, Chaly T, Kingsley PB, Kumra S, Abdelmessih S, Eidelberg D, (2008) Cerebral glucose metabolism and D2/D3 receptor availability in young adults with cannabis dependence measured with positron emission tomography. Psychopharmacology (Berl) 197: 549-556.
39. Staley JK, Krishnan-Sarin S, Zoghbi S, Tamagnan G, Fujita M, Seibyl JP, Maciejewski PK, O'Malley S, Innis RB, (2001) Sex differences in [123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse 41: 275-284.
40. Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM, (2009) Can recreational doses of THC produce significant dopamine release in the human striatum? Neuroimage 48: 186-190.
41. Takahashi H, Fujimura Y, Hayashi M, Takano H, Kato M, Okubo Y, Kanno I, Ito H, Suhara T, (2008) Enhanced dopamine release by nicotine in cigarette smokers: a double-blind, randomized, placebo-controlled pilot study. Int J Neuropsychopharmacol 11: 413-417.
42. Tanda G, Pontieri FE, Di Chiara G, (1997) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276: 2048-2050.
43. Tupala E, Hall H, Mantere T, Rasanen P, Sarkioja T, Tiihonen J, (2003) Dopamine receptors and transporters in the brain reward circuits of type 1 and 2 alcoholics measured with human whole hemisphere autoradiography. Neuroimage 19: 145-155.
44. Valjent E, Mitchell JM, Besson MJ, Caboche J, Maldonado R, (2002) Behavioural and biochemical evidence for interactions between delta 9-tetrahydrocannabinol and nicotine. Br J Pharmacol 135: 564-578.
45. Volkow ND, Fowler JS, Wang GJ, (2004) The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology 47 (Suppl. 1): 3-13.
46. Volkow ND, Fowler JS, Wang GJ, Baler R, Telang F, (2009) Imaging dopamine's role in drug abuse and addiction. Neuropharmacology 56 (Suppl. 1): 3-8.
47. Volkow ND, Fowler JS, Wang GJ, Swanson JM, Telang F, (2007) Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch Neurol 64: 1575-1579.
48. Xiao ZW, Cao CY, Wang ZX, Li JX, Liao HY, Zhang XX, (2006) Changes of dopamine transporter function in striatum during acute morphine addiction and its abstinence in rhesus monkey. Chin Med J (Engl) 119: 1802-1807.
49. Yang YK, Yao WJ, McEvoy JP, Chu CL, Lee IH, Chen PS, Yeh TL, Chiu NT, (2006) Striatal dopamine D2/D3 receptor availability in male smokers. Psychiatry Res 146: 87-90.
50. Yang YK, Yao WJ, Yeh TL, Lee IH, Chen PS, Lu RB, Chiu NT, (2008) Decreased dopamine transporter availability in male smokers-a dual isotope SPECT study. Prog Neuropsychopharmacol Biol Psychiatry 32: 274-279.
51. Yasuno F, Ota M, Ando K, Ando T, Maeda J, Ichimiya T, Takano A, Doronbekov TK, Fujimura Y, Nozaki S, Suhara T, (2007) Role of ventral striatal dopamine D1 receptor in cigarette craving. Biol Psychiatry 61: 1252-1259.